Focused On-demand Libraries - Receptor.AI Collaboration


Explore the Potential with AI-Driven Innovation

Our detailed focused library is generated on demand with advanced virtual screening and parameter assessment technology powered by the Receptor.AI drug discovery platform. This method surpasses traditional approaches, delivering compounds of better quality with enhanced activity, selectivity, and safety.


The compounds are cherry-picked from the vast virtual chemical space of over 60B molecules. The synthesis and delivery of compounds is facilitated by Reaxense.


The library includes a list of the most effective modulators, each annotated with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Furthermore, each compound is shown with its optimal docking poses, affinity scores, and activity scores, offering a detailed summary.


Our high-tech, dedicated method is applied to construct targeted libraries for enzymes.


 

Fig. 1. The screening workflow of Receptor.AI

It includes in-depth molecular simulations of both the catalytic and allosteric binding pockets, with ensemble virtual screening focusing on their conformational flexibility. For modulators, the process includes considering the structural shifts due to reaction intermediates to boost activity and selectivity.


Several key aspects differentiate our library:


  • Receptor.AI compiles an all-encompassing dataset on the target protein, including historical experiments, literature data, known ligands, and structural insights, maximising the chances of prioritising the most pertinent compounds.

  • The platform employs state-of-the-art molecular simulations to identify potential binding sites, ensuring the focused library is primed for discovering allosteric inhibitors and binders of concealed pockets.

  • Over 50 customisable AI models, thoroughly evaluated in various drug discovery endeavours and research projects, make Receptor.AI both efficient and accurate. This technology is integral to the development of our focused libraries.

  • In addition to generating focused libraries, Receptor.AI offers a full range of services and solutions for every step of preclinical drug discovery, with a pricing model based on success, thereby reducing risk and promoting joint project success.


PARTNER
Receptor.AI
 
UPACC
Q969S2

UPID:
NEIL2_HUMAN

ALTERNATIVE NAMES:
DNA glycosylase/AP lyase Neil2; DNA-(apurinic or apyrimidinic site) lyase Neil2; Endonuclease VIII-like 2; Nei homolog 2; Nei-like protein 2

ALTERNATIVE UPACC:
Q969S2; B4DFR7; Q7Z3Q7; Q8N842; Q8NG52

BACKGROUND:
The protein Endonuclease VIII-like 2, also referred to as DNA-(apurinic or apyrimidinic site) lyase Neil2, is integral to the base excision repair process, targeting DNA damage caused by oxidative stress and mutagens. It has a specific affinity for 5-hydroxyuracil among other oxidized cytosine derivatives in mismatched double-stranded DNA. The protein's ability to cleave the DNA backbone through beta-delta elimination underscores its critical role in repairing and maintaining DNA integrity.

THERAPEUTIC SIGNIFICANCE:
The exploration of Endonuclease 8-like 2's function in DNA repair presents a promising avenue for developing novel therapeutic approaches. Its pivotal role in correcting oxidative DNA damage suggests potential applications in treating diseases linked to genomic instability.

Looking for more information on this library or underlying technology? Fill out the form below and we will be in touch with all the details you need.